PharmaCyte Sets Reverse Stock Split as Nasdaq $1 Bid Deadline Looms
PMCB sits 37% above its 52-week low of $0.302.
Summary
PharmaCyte's board approved a 1-for-19 reverse stock split, a mechanical share-count change aimed squarely at the Nasdaq $1.00 minimum bid requirement it must meet by November 30. The stock last traded around $0.41, so a reverse split is the standard route to lift the quoted price above the threshold. This comes after a rough stretch: the September 10-Q showed a $5.08 million quarterly loss and material weaknesses in financial controls, and the company swapped auditors in October, dismissing CBIZ and engaging Grassi effective October 14, 2026. The split itself creates no value — it only resets the share count and price — but it is the company's main lever to avoid delisting. Watch whether the post-split price holds above $1.00 through the November 30 deadline.
At the time of this announcement, PMCB was trading at $0.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3M. The 52-week trading range was $0.30 to $1.51. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.